Phase 3 Clinical Trials With Primary Completion Dates in December 2019
This is a list of Phase 3 trials with primary completion dates in December 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 2019-12-01 | Phase 3 | NCT03681184 | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 |
| APLS | Apellis Pharmaceuticals, Inc. | 2019-12-01 | Phase 3 | NCT03500549 | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH |
| ATNM | Actinium Pharmaceuticals, Inc. | 2019-12-01 | Phase 3 | NCT02665065 | Study of Iomab-B Prior to Hematopoietic Cell Transplant vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia |
| AXSM | Axsome Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT04019704 | A Trial of AXS-05 in Patients With Major Depressive Disorder |
| AXSM | Axsome Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT03896009 | Maximizing Outcomes in Treating Acute Migraine |
| CVM | Cel-Sci Corporation | 2019-12-01 | Phase 3 | NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| GBT | Global Blood Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT03573882 | Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031 |
| GMDA | Gamida Cell Ltd. | 2019-12-01 | Phase 3 | NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS) |
| IMMU | Immunomedics, Inc. | 2019-12-01 | Phase 3 | NCT02574455 | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer |
| KMDA | Kamada Ltd. | 2019-12-01 | Phase 3 | NCT02912845 | Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies |
| MCRB | Seres Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT03183128 | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection |
| MESO | Mesoblast Limited | 2019-12-01 | Phase 3 | NCT02032004 | Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. |
| MITO | Stealth BioTherapeutics Corp. | 2019-12-01 | Phase 3 | NCT03323749 | A Trial to Evaluate the Safety and Efficacy of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Extension |
| MMSI | Merit Medical Systems, Inc. | 2019-12-01 | Phase 3 | NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer |
| MNK | Mallinckrodt plc | 2019-12-01 | Phase 3 | NCT03511625 | The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis |
| NEPH | Nephros, Inc. | 2019-12-01 | Phase 3 | NCT02757872 | Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives |
| NTEC | Intec Pharma Ltd. | 2019-12-01 | Phase 3 | NCT02615873 | A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 |
| NVAX | Novavax, Inc. | 2019-12-01 | Phase 3 | NCT04120194 | Phase 3 Pivotal Trial of NanoFlu⢠in Older Adults |
| OBSV | ObsEva SA | 2019-12-01 | Phase 3 | NCT03758885 | Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF |
| OCUL | Ocular Therapeutix, Inc. | 2019-12-01 | Phase 3 | NCT04050865 | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis |
| OPK | Opko Health, Inc. | 2019-12-01 | Phase 3 | NCT03874013 | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency |
| RDUS | Radius Health, Inc. | 2019-12-01 | Phase 3 | NCT03512262 | Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) |
| RYTM | Rhythm Pharmaceuticals, Inc. | 2019-12-01 | Phase 3 | NCT03287960 | Setmelanotide for the Treatment of LEPR Deficiency Obesity |
| SLGL | Sol-Gel Technologies Ltd. | 2019-12-01 | Phase 3 | NCT03761784 | A Study of S6G5T-3 in the Treatment of Acne Vulgaris |
| SLGL | Sol-Gel Technologies Ltd. | 2019-12-01 | Phase 3 | NCT03727074 | Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream |
| SLNO | Soleno Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT03714373 | Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome |
| SLNO | Soleno Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT03440814 | A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome |
| SNGX | Soligenix, Inc. | 2019-12-01 | Phase 3 | NCT02448381 | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
| SNY | Sanofi | 2019-12-01 | Phase 3 | NCT03529123 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) |
| SNY | Sanofi | 2019-12-01 | Phase 3 | NCT04024228 | Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older |
| TEVA | Teva Pharmaceutical Industries Limited | 2019-12-01 | Phase 3 | NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| TGTX | TG Therapeutics, Inc. | 2019-12-01 | Phase 3 | NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) |
| VNDA | Vanda Pharmaceuticals Inc. | 2019-12-01 | Phase 3 | NCT03568331 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis |
| ZGNX | Zogenix, Inc. | 2019-12-01 | Phase 3 | NCT03355209 | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome |
| ZGNX | Zogenix, Inc. | 2019-12-01 | Phase 3 | NCT02823145 | An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome |
| ZGNX | Zogenix, Inc. | 2019-12-01 | Phase 3 | NCT02682927 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome |